Paid Plans
Want to analyze multiple companies at once? Paid plans let you compare up to 5 stocks side by side.
Sign Up
D
223250
vs
K
KOSPI 200
Over the past 12 months, DreamCIS Inc has underperformed KOSPI 200, delivering a return of -27% compared to KOSPI 200's +79% growth.
Stocks Performance
223250 vs KOSPI 200
Performance Gap
223250 vs KOSPI 200
Performance By Year
223250 vs KOSPI 200
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
DreamCIS Inc
Glance View
DreamCIS is a South Korean contract research organization that helps drug makers run clinical trials and prepare medicines for regulatory approval. It works behind the scenes for pharmaceutical and biotech customers that need support with trial planning, site management, data handling, and clinical documentation. Its role is to act as a technical service provider between the companies developing new drugs and the hospitals, researchers, and regulators involved in testing them. The company makes money by charging fees for these research and development services. Its customers are mainly drug companies, biotech firms, and other healthcare groups that need outside help to move a medicine through the clinical development process. That makes DreamCIS different from a typical manufacturer or distributor: it earns its income from specialized know-how, project management, and regulatory execution rather than from selling a physical product.